The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib.
Josef J. Fox
No relevant relationships to disclose
Eric C. Haupt
No relevant relationships to disclose
John Humm
No relevant relationships to disclose
Karen A. Autio
No relevant relationships to disclose
Dana E. Rathkopf
No relevant relationships to disclose
Hebert Alberto Vargas
No relevant relationships to disclose
Heiko Schöder
No relevant relationships to disclose
Hedvig Hricak
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose